A ranar 22 ga Oktoba, agogon Gabas.FDA ta Amurkabisa hukuma ta amince da Veklury antiviral na Gileyad (remdesivir) don amfani da manya masu shekaru 12 zuwa sama kuma suna auna aƙalla kilogiram 40 cikin buƙatar asibiti da kuma COVID-19 magani.Dangane da FDA, a halin yanzu Veklury shine kawai maganin COVID-19 da FDA ta amince da shi a cikin Amurka.

Wannan labarin ya shafa, hannun jarin Gileyad ya karu da kashi 4.2% bayan kasuwa.Yana da kyau a lura cewa a baya Trump ya bayyana a bainar jama'a cewa Remdesivir "muhimmin magani ne ga marasa lafiya da ke da sabon ciwon huhu" kuma ya bukaci FDA da ta amince da maganin cikin gaggawa.Bayan an gano shi da sabon ciwon huhu, ya kuma karbi Remdesivir.

A cewar "Financial Times” rahoton, masana kimiyya sun nuna damuwa game da amincewa.Irin wannan damuwar dai na da nasaba da yadda za a gudanar da zaben shugaban kasar Amurka nan da makonni biyu masu zuwa.Amincewar FDA na iya kasancewa saboda matsin lamba na siyasa, kuma ya zama dole a nuna yadda gwamnati ke ba da amsa ga cutar.A cikin watan Mayun bana, tsohon shugaban kasar Amurka Barack Obama ya soki matakin da gwamnatin Trump ta dauka kan sabuwar annobar cutar huhu, inda ya kira ta a matsayin annoba."gaba daya m bala'i."

Baya ga dalilai na siyasa, a taron manema labarai na yau da kullun na WHO game da sabbin cututtukan huhu a ranar 16 ga Oktoba, Darakta Janar na WHO Tedros ya ce sakamakon tsakiyar wa'adi na "gwajin hadin kai" ya nuna cewa remdesivir da hydroxychloroquine, Lopinavir/ritonavir da interferon therapy. da alama ba ta da tasiri kan adadin mace-macen kwanaki 28 ko kuma tsawon zaman asibiti a majinyatan asibiti.Gwajin na WHO ya nuna cewa Redecivir ba ya aikia lokuta masu tsanani.301 daga cikin 2743 marasa lafiya marasa lafiya a cikin kungiyar Redeive sun mutu, kuma 303 daga cikin 2708 marasa lafiya marasa lafiya a cikin ƙungiyar kulawa sun mutu;adadin wadanda suka mutu ya kai 11, bi da bi.% Kuma 11.2%, da kuma kwanaki 28 na mace-mace na Remdesivir da ƙungiyar kulawa sun cika sosai, kuma kusan babu wani gagarumin bambanci.

Amma kafin sakamakon wannan gwajin hadin kai da taimakon juna ya fito.Gileyad ya gabatar da shi don amincewa a watan Agusta.

Yarda da Remdesivir ya dogara ne akan sakamakon gwaje-gwajen asibiti da aka sarrafa bazuwar da suka haɗa da marasa lafiyar da aka kwantar da su a asibiti saboda tsananin COVID-19.Wani bazuwar, makafi biyu, gwajin asibiti mai sarrafa wuribo wanda Cibiyar Kula da Allergy da Cututtuka ta Kasa ta gudanar ta kimanta lokacin da ake ɗaukar marasa lafiya don murmurewa daga COVID-19 a cikin kwanaki 29 na karbar magani.Gwajin ya lura da marasa lafiya 1062 masu laushi, matsakaici, da matsananciyar COVID-19 waɗanda aka shigar da su asibiti kuma sun karɓi remdesivir (mutane 541) ko placebo (mutane 521), da daidaitaccen magani.Tsakanin lokacin dawowa daga COVID-19 shine kwanaki 10 a cikin rukunin remdesivir da kwanaki 15 a cikin rukunin placebo, kuma bambancin ya kasance mai mahimmanci a ƙididdiga.Gabaɗaya, idan aka kwatanta da ƙungiyar placebo, damar inganta asibiti a ranar 15 a cikin rukunin Remdesivir ya kasance mai girma sosai.

Shugaban FDA, Stephen Hahn, ya ce wannan amincewar tana samun goyan bayan bayanai daga gwaje-gwajen asibiti da yawa waɗanda hukumar ta yi nazari sosai kuma suna wakiltar wani muhimmin ci gaba na kimiyya.r sabon kambi annoba.